跳转至内容
Merck

Y0000609

2-氯-2′-脱氧腺苷

European Pharmacopoeia (EP) Reference Standard

别名:

2-Chloro-2′-deoxyadenosine, CdA, Cladribine

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C10H12ClN5O3
CAS号:
分子量:
285.69
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

cladribine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

Nc1nc(Cl)nc2n(cnc12)[C@H]3C[C@H](O)[C@@H](CO)O3

InChI

1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1

InChI 密鑰

PTOAARAWEBMLNO-KVQBGUIXSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Cladribine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 3 Oral - Muta. 2 - Repr. 2 - STOT RE 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Philippa L Kohnke et al.
Journal of proteome research, 11(9), 4436-4448 (2012-07-31)
Fludarabine and cladribine are purine analogues used to treat hematological malignancies. Alone or in combination with therapeutic antibodies, they are effective in treating patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma. However, the mechanisms of action of these drugs are
Tomasz Bączek et al.
Journal of pharmaceutical and biomedical analysis, 70, 330-336 (2012-06-05)
Individualization of the topotecan dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. Topotecan dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the topotecan systemic exposure
Naveen Mulakayala et al.
European journal of medicinal chemistry, 60, 170-186 (2013-01-08)
Multiple sclerosis (MS) often results in chronic inflammatory and autoimmune disorders, and recent developments in understanding the disease pathogenesis has lead to newer therapeutic options for the treatment of the disease. The development of small molecule drugs with improved efficacy
Jeffrey E Rubnitz et al.
Cancer, 118(24), 6253-6259 (2012-06-08)
Older age has historically been an adverse prognostic factor in pediatric acute myeloid leukemia (AML). To the authors' knowledge, the impact of age relative to that of other prognostic factors on the outcome of patients treated in recent trials is
Vikramjeet Singh et al.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(4), 939-950 (2012-07-24)
2-chlorodeoxyadenosine (CdA, Cladribine) is an immunosuppressant that has recently been shown to be effective in the treatment of multiple sclerosis (MS). There is extensive clinical experience with CdA for the treatment of neoplastic diseases, especially hematologic malignancies, due to its

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门